In AD patients, TGFβ is decreased in plasma but increased in CSF [132], TβRII expression is reduced in the brain, the phosphorylation of SMAD2/3 and its subcellular location are also altered in the diseased brain [137]. This evidence concerns the gene TGFB1 and Alzheimer disease.